After discussions with the FDA, Moderna has withdrawn its application for a combination shot, which had demonstrated efficacy in eliciting antibodies in data announced earlier this month.

Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

SEOUL: SK bioscience, the biopharmaceutical arm of South Korea's SK Group, said on Wednesday it has achieved a "final victory" in a patent invalidation case against Moderna, the global developer of ...

Moderna conducted a study to test a combination COVID-19 and flu shot. Researchers tested the shot on 8,000 adults. The pharmaceutical and biotechnology company is targeting 2026 for approval of ...

The mRNA technology is used in approved COVID-19 and RSV shots, but has not yet been approved for a flu shot. Moderna believes ... “I agree in this case with FDA that efficacy data are important ...

Federal cuts could sink them Researchers from vaccine-maker Moderna reported in a study published Wednesday that the new combo shot generated a stronger immune response against COVID-19 and most ...

Researchers from Cambridge-based vaccine-maker Moderna reported in a study published Wednesday that the new combo shot generated a stronger immune response against COVID-19 and most strains of flu ...

Researchers from vaccine-maker Moderna reported in a study published Wednesday that the new combo shot generated a stronger immune response against COVID-19 ... agree in this case with FDA that ...